Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Jacksonville, Florida 32224


Purpose:

The purpose of this study is to see how much gabapentin will reduce headaches associated with subarachnoid hemorrhage (SAH) and to reduce the amount of narcotic pain medication prescribed.


Study summary:

We plan to use gabapentin (GBP), an FDA approved non-narcotic pain medication for neuropathic pain, which is also an alpha-2-delta (A2DR) receptor analogue to reduce the pain and decrease the need for narcotics in patients with aneurysmal subarachnoid hemorrhage (aSAH). GBP has been shown to decrease neuropathic and non-neuropathic pain in a variety of perioperative and postoperative conditions. A2DR affinity also has some neuroprotective effect in animal data. We plan to conduct a prospective, double-blinded, randomized trial to further assess GBP-associated reductions in narcotic use and pain scores compared to the non-GBP (placebo) arm. To accomplish this aim, we plan to randomize 20 aSAH patients with headache to either GBP and standard of care pain treatment versus placebo and standard of care treatment.


Criteria:

Inclusion Criteria: 1. 18 years of age or older 2. Have aneurysmal subarachnoid hemorrhage (aSAH) diagnosed by CT scan of the brain and/or angiogram evidence of intracranial aneurysm (CTA or digital subtraction angiogram or MRA) 3. Have symptomatic headache 4. Able to swallow and verbalize pain score 5. No known allergy to gabapentin or fentanyl 6. Numeric pain score ≥ 5 7. Ability to provide written personal consent Exclusion Criteria: 1. Gabapentin use prior to SAH admission 2. Renal failure with creatinine clearance less than 30 mL/min 3. Unable to receive standard of care pain medications 4. Pregnant or breastfeeding patients 5. History of severe depression defined by DSM IV


NCT ID:

NCT02330094


Primary Contact:

Principal Investigator
William Freeman, MD
Mayo Clinic


Backup Contact:

N/A


Location Contact:

Jacksonville, Florida 32224
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 17, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.